---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-003488"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:49:09.172921+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Arrowhead reports Q1 revenue of $3.55M, down 94% YoY; operating loss $136.5M; cuts cash burn by up to $100M

## Summary
- Revenue $3.55M vs $62.55M YoY; net loss $132.9M ($1.24 EPS) from $41.3M ($0.39 EPS) loss prior year.
- Operating expenses $140.1M (R&D $116.5M, G&A $23.6M); operating loss $136.5M.
- Cuts forward cash burn guidance by up to $100M (~$30M/qtr); completed $450M stock offering.
- Terminated ARO-SOD1 and HZN-457; focuses on cardiometabolic, pulmonary programs; hired interim chief medical scientist.

## SEC filing metadata
- accession: 0001628280-24-003488
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828024003488/0001628280-24-003488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828024003488/arwr-20240206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-003488
- JSON: https://secwatch.observer/filing/0001628280-24-003488.json
- Plain text: https://secwatch.observer/filing/0001628280-24-003488.txt

## Key facts
- Earnings Releases
  ARROWHEAD PHARMACEUTICALS, INC. reported fiscal 2024 first quarter ended December 31, 2023 results: revenue $ 3,551, net income $ (132,864), EPS $ (1.24).
  - Period: fiscal 2024 first quarter ended December 31, 2023
  - Revenue: $ 3,551
  - Net income: $ (132,864)
  - EPS: $ (1.24)
  - Result: reported results
  source text: INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Year Ended December 31, OPERATING SUMMARY 2023 2022 (Unaudited) Revenue $ 3,551 $ 62,546 Operating Expenses: Research and development 116,491 83,695 General and administrative expenses 23,605 20,985 Total Operating Expenses 140,096 104,680 Operating loss
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828024003488/0001628280-24-003488-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.